Boston Scientific (BSX) is set to open the week near recent lows after its shares plummeted 16.4% last week, closing at $48.31 on May 29. The sharp selloff followed CEO Michael Mahoney's comments at the Bernstein conference, where he flagged "declining usage" of the company's key Watchman heart implant and forecasted flat dollar growth through the third quarter. The decline marks the stock's fourth consecutive losing session, with trading volume nearly doubling the 50-day average to 37.1 million shares on Friday.
Watchman Under Pressure
The Watchman device, designed to prevent blood clots in atrial fibrillation patients by closing off the left atrial appendage, has been a critical growth driver for Boston Scientific. However, standalone case volumes are slipping, raising concerns about whether the slowdown is temporary or signals a longer-term erosion of market share. J.P. Morgan analyst Robbie Marcus noted that the update "pushes off" a verdict on whether management has rebuilt investor trust. The company now expects flat revenue from Q1 to Q2, with the trend potentially persisting through Q3.
Competitive Landscape Heats Up
The weakness appears specific to the left atrial appendage closure market rather than a broad medical-device slowdown. Rivals Abbott (ABT), Medtronic (MDT), and AtriCure (ATRC) have ramped up competition in this space, intensifying pressure on Boston Scientific. Wells Fargo analyst Larry Biegelsen downgraded the stock to Equal Weight from Overweight, slashing the price target to $55 from $75, citing the Watchman headwinds. The downgrade added to the selling pressure on Friday.
Market Context and Buyback
Despite the selloff, broader U.S. markets finished higher on Friday, with the S&P 500 posting its seventh consecutive gain and ninth weekly advance. Boston Scientific's decline stood out against this strong backdrop. The company has initiated a $2 billion accelerated share repurchase agreement, announced on May 18, with final settlement expected by June 30. An additional $3 billion remains under its existing authorization. However, analysts caution that a buyback alone cannot resolve the underlying demand issues for Watchman.
Outlook and Key Dates
Boston Scientific's next earnings call is scheduled for July 29, leaving the stock to trade on news flow and analyst commentary in the interim. Investors will be watching for any procedural data or management statements that could clarify the trajectory of Watchman usage. Bargain hunters may step in if the weakness proves temporary, but the risk of further estimate cuts remains high if the slowdown is structural. The stock now trades less on overall med-tech momentum and more on whether management can convince the market that the Watchman floor holds.
